INTRODUCTION
Diabetic retinopathy (DR) is ranked as the most severe ocular complication of diabetes mellitus (DM) and remains a major cause of vision loss in many countries (Rizyal, 2004) . Chronic inflammation develops in the retinal microvasculature under sustained hyperglycemia (Abu El-Asrar et al., 1992; Meleth et al., 2005) and is implicated in the pathogenesis of diabetic retinopathy. Proliferative DR (PDR) is followed by recurrent vitreous hemorrhages, traction retinal detachment, retinal and vitreous fibrosis, and optic nerve atrophy, which finally lead to severe visual impairments (Abu El-Asrar et al., 2006; Bhavsar, 2006; Lim et al., 2008) . Retinal neovascularization (RNV) is the most striking characteristic of PDR (Du et al., 2014) and involves various angiogenic factors such as cytokines, inflammatory cells, and growth factors (Adamis, 2002; Abu El-Asrar et al., 2006; Patel et al., 2006) . Previous studies have also emphasized the role of vascular endothelial growth factor (VEGF) and other factors with angiogenic properties in the pathogenesis of PDR (Citirik et al., 2012; Mohan et al., 2012; Pennock and Kazlauskas, 2012) . It is known that disturbances or functional imbalance of the immune system as well as activation of vascular proliferation contribute to the pathogenesis of PDR (Murugeswari et al., 2008; Kowluru et al., 2010; Suzuki et al., 2011; Symeonidis et al., 2011) . However, the interactions between the pro/anti-inflammatory cytokines and angiogenic factors in PDR remain to be explored.
Several members of the tumor necrosis factor (TNF) superfamily have recently been found to regulate inflammation and neovascularization (Burkly et al., 2007; Sethi et al., 2009; Zhang and Li, 2012) . In particular, TNF-like weak inducer of apoptosis (TWEAK) activates the nuclear factor-κB signal (Polavarapu et al., 2005) transduction pathway by binding to fibroblast growth factorinducible molecule 14 (Fn14), a member of the TNF receptor superfamily (Haile et al., 2010) , and exerts critical control of the inflammatory response and proangiogenic reactions (Burkly et al., 2007; Winkles, 2008) . In addition, TWEAK has been reported to promote the levels of pro-inflammatory molecules such as matrix metalloproteinase-9 (MMP-9), intercellular adhesion molecule-1 (ICAM-1), and interleukin (IL)-6 (Harada et al., 2002; Kamijo et al., 2008) , all of which are involved in the pathogenesis of PDR. Furthermore, considerable evidence suggested a proangiogenic role for TWEAK (Lynch et al., 1999; Donohue et al., 2003; Ho et al., 2004) . Therefore, we speculate that the TWEAK/Fn14 pathway may modulate PDR.
The goal of the current study was to determine the expression of the TWEAK/Fn14 pathway in PDR, and to confirm the correlation between TWEAK expression and clinicopathological characteristics of PDR. We also wanted to investigate the regulatory roles of the TWEAK/Fn14 pathway in cell proliferation and collagen synthesis in retinal ARPE-19 cells.
MATERIAL AND METHODS

Vitreous samples, ARPE-19 cell culture, and TWEAK overexpression
Vitreous fluid samples (200-500 µL) were obtained from 16 PDR patients and 21 type 2 diabetic (T2D) patients who had undergone vitrectomy. Both groups were enrolled between June 2013 and August 2014 in the Department of Ophthalmology at Jilin University Second Affiliated Hospital. Written consent was given by all patients for the use of vitreous fluid samples in the study. Approval was also obtained from the Ethics Committee of the Second Affiliated Hospital. Detailed characteristics regarding the PDR patients and T2D patients without PDR are outlined in Table 1 .
Following sample collection, vitreous fluids were centrifuged (1000 rpm for 10 min, 4°C) to remove cellular debris and were frozen as individual aliquots at -80°C until further use. ARPE-19 cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) and were cultured in Dulbecco's Modified Eagle Medium + Nutrient Mixture F-12 (DMEM/F-12) (GIBCO, Rockville, MD, USA) supplemented with 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA, USA), 100 U/mL penicillin, and 100 mg/mL streptomycin (CSPC Pharmaceutical Group Limited, Shijiazhuang, China) at 37°C and 5% CO 2 . Cells at greater than 90% confluence were sub-cultured at a ratio of 1:3.
To overexpress TWEAK in ARPE-19 cells, the human TWEAK coding sequence was amplified (Sinobio, Beijing, China) and cloned into a pcDNA3.1(+) vector (Invitrogen). Enhanced green fluorescence protein (EGFP) coding sequence was also cloned into the vector as a control pcDNA3.1(+). TWEAK-pcDNA3.1(+) or control pcDNA3.1(+) plasmids were transfected into ARPE-19 cells with Lipofectamine 2000 (Invitrogen). Cells with successful integration of the target genes TWEAK or EGFP were selected using 1.5 mg/mL G418 (Thermo Scientific, Rockford, IL, USA), and were maintained in media containing 800 ng/mL G418.
RNA extraction and quantitative real-time polymerase chain reaction
Quantitative real-time PCR (qRT-PCR) was performed using QuantiTect SYBR Green PCR Kits (Qiagen, GmbH, Hilden, Germany) following the manufacturer protocol, with GAPDH as an internal control. qPCR was performed on an ABI PRISM 7300 detection system with the following cycling parameters: 95°C for 5 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. Primers for TWEAK, Fn14, and GAPDH were synthesized by the Sangon company (Shanghai, China). All data are reported as fold change over the internal control, and were calculated using the ∆∆Ct method (Schmittgen and Livak, 2008) . 
Western blot analysis of TWEAK and Fn14 in vitreous samples or cells
ARPE-19 cells for western blot assays were collected and lysed with Cell Lysis Solutions
Cell count assay, MTT assay, and colony formation assay
Growth curves of ARPE-19 (TWEAK+) and ARPE-19 (control) cells were determined via cell count assays. Briefly, ARPE-19 (TWEAK+) and ARPE-19 (control) cells were seeded on 12-well plates with an initial cell number of 10 4 cells/mL. Cells were cultured at 37°C for 1, 3 or 5 days. Cells in each well were then trypsinized, stained with Trypan blue, and counted in a hemocytometer.
Cellular viability was assayed using the MTT method. ARPE-19 (TWEAK+) and ARPE-19 (control) cells were seeded on 96-well plates, and were allowed to grow to 85-90% confluence. Media (DMEM/F-12 supplemented with 2% FBS) were replaced, and the cells were cultured at 37°C for another 8, 24 or 48 h. This was followed by the addition of MTT (20 µL/well) to each well, and the plates were incubated for an additional 2h. MTT was then removed, and dimethyl sulfoxide was added to dissolve formazan products. Finally, the OD570 was measured on a microplate spectrophotometer.
For the colony formation assay, 200 or 500 cells per well in each group were seeded onto a 12-well plate. After 4 days, cell colonies were stained with 0.5% crystal violet (Beijinghuagong, Beijing, China) and were counted.
Statistical analysis
Statistical analyses were performed using GraphPad Prism (GraphPad Software, La Jolla, CA, USA). Quantitative results are reported as means ± standard error of the mean. Comparisons between the two groups (mRNA and protein expression of TWEAK and Fn14, cell number, colony number) were carried out using the Student t-test. Statistical significance was reached when P < 0.05.
RESULTS
PDR patients have elevated levels of TWEAK in vitreous fluids
In the present study, 21 patients with T2DM (without PDR) and 16 patients with PDR were recruited. The clinical characteristics of patients in the two groups are presented in Table 1 . There was no significant difference in age, gender, body mass index (BMI), C-reactive protein (CRP), or hemoglobin A1c (HbA1c) between the PDR group and the T2DM group. However, serum levels of both triglycerides and total cholesterol were significantly higher in the PDR patients as compared to the control T2DM patients (P < 0.01). In addition, duration of DM for the PDR patients was significantly longer as compared with T2DM patient without PDR (P < 0.01). In order to determine a possible role of TWEAK in PDR, we examined the vitreous level of TWEAK in each group of patients by using ELISA. As shown in Figure 1A , the TWEAK level in control T2DM patients was 1.64 ± 0.56 ng/mL (N = 21), whereas in the PDR patients (N = 16), it was 2.96 ± 1.14 ng/mL (N = 16), which was significant higher (P < 0.001). The level of the receptor for TWEAK, Fn14, was also significantly higher in the PDR group as compared to the control group (5.37 ± 1.64 vs 3.85 ± 0.78 ng/mL, P < 0.01, Figure 1B) . We further examined protein expression of these two molecules via western blot assays. As shown in Figure 1C -E, there was also a significant difference in the levels of TWEAK and Fn14 of the PDR and control T2DM groups (P < 0.001). Therefore, it is possible that TWEAK/Fn14 signaling is upregulated in vitreous fluids of PDR patients. 
Construction of a TWEAK-overexpressing ARPE-19 cell line
We overexpressed TWEAK in retinal ARPE-19 cells in order to determine the role of TWEAK inARPE-19 cell proliferation. Figure 2A shows the strategy used for TWEAK overexpression. The TWEAK-coding sequence was cloned into the pcDNA3.1(+) vector, and ARPE-19 cells were transfected with the recombinant TWEAK-pcDNA3.1(+) plasmid. Successful transfections were selected under the using the antibiotic G418 (1.2 μg/mL), and positive cell clones were propagated in the presence of 0.8 μg/mL G418. Both mRNA ( Figure 2B ) and protein ( Figure 2C and D) expression of TWEAK was significantly elevated in ARPE-19 (TWEAK+) cells as compared to that in ARPE-19 (control) cells (P < 0.001). This effect persisted despite further serial cell passages. (Con) cells, with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as an internal control. Quantitative data were averaged for three independent results. **P < 0.01, ***P < 0.001, ns: no significance.
TWEAK overexpression promotes cell proliferation and collagen synthesis of retinal cells
To investigate the regulatory role of TWEAK on the proliferation of ARPE-19 cells, we curved the growth of ARPE-19 (TWEAK+) and ARPE-19 (control) cells. As shown in Figure 3A , ARPE-19 (TWEAK+) experienced faster growth as compared to ARPE-19 (control) cells at 3 and 5 days post inoculation (P < 0.01). We also examined the viability of ARPE-19 (TWEAK+) and ARPE-19 (control) cells in media supplemented with 2% FBS. As indicated in Figure 3B , ARPE-19 (TWEAK+) cells were more viable than ARPE-19 (control) cells at both 24 and 48 h post inoculation (P < 0.05). To further evaluate the growth difference between the two types of cells, we performed colony-forming assays on these cells. We found that regardless of the number of initially inoculated cells, significantly more colonies were formed by ARPE-19 (TWEAK+) cells as compared to ARPE-19 (control) cells (either P < 0.01) (Figure 3C and D) . Furthermore, colonies formed by ARPE-19 (TWEAK+) cells were larger than those formed by ARPE-19 (control) cells. Thus, we confirmed that overexpression of TWEAK leads to increased cell proliferation in retinal ARPE-19 cells. To further confirm the role of TWEAK in the pathogenesis of PDR, we then examined the expression of fibrosis-associated molecules such as α-SMA, collagen I, and collagen IV in both ARPE-19 (TWEAK+) and ARPE-19 (control) cells. Western blot analysis ( Figure 4A ) indicated that there was a significant increase in α-SMA (Figure 4B ), collagen I ( Figure 4C ), and collagen IV ( Figure 4D ) expression in ARPE-19 (TWEAK+) cells as compared to the levels in ARPE-19 (control) cells (either P < 0.001). These observations suggest that TWEAK can increase the production of fibrosis-associated molecules in retinal cells. 
DISCUSSION
It has recently been suggested that TWEAK and Fn14 are upregulated in vitreous fluids of patients with PDR (Abu El-Asrar et al., 2015) . Specifically, TWEAK protein was found to be localized in vascular endothelial cells, mononuclear cells, and myofibroblasts in PDR epiretinal membranes (Abu El-Asrar et al., 2015) . In addition, TWEAK was reported to be over expressed in synovial fibroblasts from patients with rheumatoid arthritis and psoriatic arthritis (van Kuijk et al., 2010) . In the present study, we examined the expression of TWEAK and Fn14 in both PDR and control T2DM patients without PDR. We confirmed that elevated levels of TWEAK and Fn14 are found in the vitreous fluid from patients with PDR, implying an important regulatory role of TWEAK/Fn14 signaling in the pathogenesis of PDR. Given the relatively low expression of Fn14 in healthy tissues, we speculated that activation of the TWEAK/Fn14 pathway is strictly controlled under normal physiological conditions, and the markedly promoted TWEAK/Fn14 pathway may be associated with the physiopathological status of PDR.
The TWEAK/Fn14 pathway has been confirmed to play important roles in biological processes such as inflammation, angiogenesis, cell death, and fibrosis. Recent reports have indicated that activation of the TWEAK/Fn14 pathway is associated with the clinical severity of autoimmune and inflammatory diseases such as rheumatoid arthritis and systemic lupus erythematosus (Winkles, 2008) . This pathway has been found to promote immune responses through its ability to induce cytokines, chemokines, and adhesion molecules (Polavarapu et al., 2005; Kamijo et al., 2008) . Accumulating evidence has also demonstrated the proangiogenic (Burkly et al., 2011) and fibrogenic (Winkles, 2008) roles of TWEAK; it has been shown to mediate collagen synthesis and fibrosis in arthritis (Kamata et al., 2006; Perper et al., 2006) as well as cardiac fibrosis (Chen et al., 2012; Novoyatleva et al., 2013) . However, the exact role of TWEAK in the pathogenesis of PDR remains unclear. In the present study, we confirmed promotion of the TWEAK/Fn14 pathway in the PDR inflammatory responses. The current study clearly indicated that the overexpression of TWEAK has a large impact on the proliferation of retinal ARPE-19 cells. The increased TWEAK in retinal ARPE-19 cells promoted proliferation and collagen synthesis in retinal cells. These results suggest that TWEAK/Fn14 upregulation in PDR may contribute to PDR progression via induction of pro inflammatory mediators, promotion of angiogenesis, and increased proliferation of retinal cells.
In conclusion, we have found increased expression of the TWEAK/Fn14 pathway in PDR. Our findings imply that TWEAK/Fn14 mediates persistent inflammation and modulation of pathological neovascularization associated with PDR.
